Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-18BP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-18BP ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View IL18BP Products |
| Gene Delivery | IL-18BP Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View IL18BP Products |
| Benchmark Ab | Anti-IL-18BP Recombinant Antibody Recombinant positive control matching clinical benchmark sequence. |
View IL18BP Products |
| Validator | IL-18BP siRNA Set For knockdown verification in functional assays. |
View IL18BP Products |
| Related Target A | IL-18 (Interleukin-18) Primary cytokine ligand bound and neutralized by IL-18BP. |
View IL18 Products |
| Related Target B | IL-18R1 (IL-18 Receptor 1) Functional signaling receptor competed by IL-18BP binding. |
View IL18R1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Subfamily counter screening | Homolog panel proteins (other IL-1 binding family members) strictly verified by theoretical MW and mass spec. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA sets included for target specificity and knockdown validation. |
Live IL-18BP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-18BP therapeutics is intensifying, with major players shifting focus from traditional recombinant proteins to monoclonal antibodies and decoy-resistant cytokine variants. As first-generation therapies reach the clinic, the next wave of R&D is targeting the disruption of the IL-18/IL-18BP immunosuppressive axis in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein | AB2 Bio (Tadekinig alfa) | Adult-onset Still's Disease (AOSD), HLH | High-concentration formulation stability assays (Need high-purity, low-endotoxin monomeric protein) |
| Monoclonal Antibody | Oncology-focused Biotechs | Solid Tumors (Immunotherapy) | Blocking assay validation (Need sequence-verified IL-18BP and IL-18 interaction pairs) |
| Decoy-Resistant Cytokine | Simcha Therapeutics | Refractory Solid Tumors | Selectivity assays against wild-type binding partners (Need recombinant WT IL-18BP as counter-screen) |